MBA MA - Lineage Cell President CEO

LCTX Stock  USD 0.52  0.09  14.75%   

CEO

MBA MA is President CEO of Lineage Cell Therapeutics
Age 53
Address 2173 Salk Avenue, Carlsbad, CA, United States, 92008
Phone442 287 8990
Webhttps://www.lineagecell.com

Lineage Cell Management Efficiency

The company has return on total asset (ROA) of (0.1286) % which means that it has lost $0.1286 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3504) %, meaning that it created substantial loss on money invested by shareholders. Lineage Cell's management efficiency ratios could be used to measure how well Lineage Cell manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.52 in 2024. Return On Capital Employed is likely to drop to -0.31 in 2024. At this time, Lineage Cell's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 65.7 M in 2024, whereas Total Current Assets are likely to drop slightly above 21.1 M in 2024.
Lineage Cell Therapeutics currently holds 2.95 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Lineage Cell Therapeutics has a current ratio of 2.95, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Lineage Cell's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 8 records

CEO Age

Maria PalasisLyra Therapeutics
59
Michael BrighamImmuCell
63
Robert CoffinReplimune Group
59
David HungNuvation Bio
63
Norbert BischofbergerKronos Bio
68
Junyuan WangNuvation Bio
51
Deborah MDArmata Pharmaceuticals
67
Barry PharmDConnect Biopharma Holdings
67
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California. Lineage Cell operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 57 people. Lineage Cell Therapeutics (LCTX) is traded on NYSE MKT Exchange in USA. It is located in 2173 Salk Avenue, Carlsbad, CA, United States, 92008 and employs 68 people. Lineage Cell is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Lineage Cell Therapeutics Leadership Team

Elected by the shareholders, the Lineage Cell's board of directors comprises two types of representatives: Lineage Cell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lineage. The board's role is to monitor Lineage Cell's management team and ensure that shareholders' interests are well served. Lineage Cell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lineage Cell's outside directors are responsible for providing unbiased perspectives on the board's policies.
Charlotte Hubbert, Vice Development
Jill Howe, CFO Officer
DVM Dvm, VP Affairs
Alexandra Hernandez, Senior Controller
William MBA, President Corporation
JD III, General Secretary
Ioana Hone, Director Relations
William Annett, Pres Corp
Rami Skaliter, Chief Neurosciences
Harold Waitz, Vice Control
MBA MA, President CEO

Lineage Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lineage Cell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lineage Stock Analysis

When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.